The Chemokine Network in Acute Myelogenous Leukemia: Molecular Mechanisms Involved in Leukemogenesis and Therapeutic Implications

2010 ◽  
pp. 149-172 ◽  
Author(s):  
Astrid Olsnes Kittang ◽  
Kimberley Hatfield ◽  
Kristoffer Sand ◽  
Håkon Reikvam ◽  
Øystein Bruserud
Keyword(s):  
Acute Myelogenous Leukemia ◽  
Molecular Mechanisms ◽  
Myelogenous Leukemia ◽  
Therapeutic Implications ◽  
Acute Myelogenous

scholarly journals Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications

Blood ◽  
1983 ◽  
Vol 62 (4) ◽  
pp. 709-721 ◽  
Author(s):  
HP Koeffler
Keyword(s):  
Cell Differentiation ◽  
Acute Myelogenous Leukemia ◽  
Early Stage ◽  
Leukemia Cell ◽  
Leukemic Cell ◽  
Myelogenous Leukemia ◽  
Leukemia Cells ◽  
Therapeutic Implications ◽  
Stage Of Development ◽  
Acute Myelogenous

Abstract A prominent phenotypic abnormality of human acute myelogenous leukemia cells is the inability of the cells to differentiate to functional mature cells; instead, the cells are blocked at an early stage of development and remain in the proliferative pool and rapidly accumulate. Investigation of the induction of myeloid leukemic cell differentiation has made recent advances with the development of several human myelogenous leukemia cell lines. The lines provide models to study the biology of myeloid differentiation and to identify inducers of differentiation of myeloid leukemic blood cells. This review critically examines the inducers of leukemic cell differentiation and their potential therapeutic importance.

Translocation t(15;17) in acute myelogenous leukemia with atypical megakaryoblastic features: Diagnostic, clinical, and therapeutic implications

1996 ◽  
Vol 92 (1) ◽  
pp. 50-53 ◽  
Author(s):  
David L. Morgan ◽  
Dale M. Dunn ◽  
Everardo Cobos ◽  
Yi-Kong Keung ◽  
Thomas S. McConnell ◽  
...  
Keyword(s):  
Acute Myelogenous Leukemia ◽  
Myelogenous Leukemia ◽  
Therapeutic Implications ◽  
Acute Myelogenous

scholarly journals Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia

Blood ◽  
2010 ◽  
Vol 116 (1) ◽  
pp. 71-80 ◽  
Author(s):  
Jianting Long ◽  
Brian Parkin ◽  
Peter Ouillette ◽  
Dale Bixby ◽  
Kerby Shedden ◽  
...  
Keyword(s):  
Acute Myelogenous Leukemia ◽  
Molecular Mechanisms ◽  
Ex Vivo ◽  
P53 Protein ◽  
Myelogenous Leukemia ◽  
External Irradiation ◽  
Primary Resistance ◽  
Acute Myelogenous ◽  
Mdm2 Inhibitor ◽  
Inhibitor Treatment

Abstract The survival of most patients with acute myelogenous leukemia (AML) remains poor, and novel therapeutic approaches are needed to improve outcomes. Given that the fraction of AML with mutated p53 is small (∼ 10%), it appears rational to study MDM2 inhibitors as therapy for AML. Here, we report results of a detailed characterization of sensitivity and resistance to treatment ex vivo with the MDM2 inhibitor MI219 in AML blasts from 109 patients. In line with previous observations, all AML cases with mutated p53 were resistant to MI219. Importantly, approximately 30% of AML cases with unmutated p53 also demonstrated primary resistance to MI219. Analysis of potential mechanisms associated with MI219 resistance in AML blasts with wild-type p53 uncovered distinct molecular defects, including low or absent p53 protein induction after MDM2 inhibitor treatment or external irradiation. Furthermore, a separate subset of resistant blasts displayed robust p53 protein induction after MI219 treatment, indicative of defective p53 protein function or defects in the apoptotic p53 network. Finally, analysis of very sensitive AML cases uncovered a strong and significant association with mutated Flt3 status (Flt3-ITD), which for the first time identified a clinically high-risk group of AML that may particularly benefit from MDM2 inhibitor treatment.

scholarly journals Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications

Blood ◽  
1983 ◽  
Vol 62 (4) ◽  
pp. 709-721 ◽  
Author(s):  
HP Koeffler
Keyword(s):  
Cell Differentiation ◽  
Acute Myelogenous Leukemia ◽  
Early Stage ◽  
Leukemia Cell ◽  
Leukemic Cell ◽  
Myelogenous Leukemia ◽  
Leukemia Cells ◽  
Therapeutic Implications ◽  
Stage Of Development ◽  
Acute Myelogenous

A prominent phenotypic abnormality of human acute myelogenous leukemia cells is the inability of the cells to differentiate to functional mature cells; instead, the cells are blocked at an early stage of development and remain in the proliferative pool and rapidly accumulate. Investigation of the induction of myeloid leukemic cell differentiation has made recent advances with the development of several human myelogenous leukemia cell lines. The lines provide models to study the biology of myeloid differentiation and to identify inducers of differentiation of myeloid leukemic blood cells. This review critically examines the inducers of leukemic cell differentiation and their potential therapeutic importance.

Sweet's syndrome associated with acute myelogenous leukemia.

1985 ◽  
Vol 47 (1) ◽  
pp. 3-10 ◽  
Author(s):  
Shuichi INADA ◽  
Taizo KOHNO ◽  
Iseko SAKAI ◽  
Yoriko SHIMAMOTO ◽  
Nobutaka IMAMURA ◽  
...  
Keyword(s):  
Acute Myelogenous Leukemia ◽  
Myelogenous Leukemia ◽  
Sweet’S Syndrome ◽  
Sweet's Syndrome ◽  
Acute Myelogenous
Sign in / Sign up

Export Citation Format

Share Document